Scarica l'app Stockscreener
757.18
0.38%
2.83
Dopo l'orario di chiusura:
759.00
1.82
+0.24%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$754.35
Aprire:
$755.57
Volume 24 ore:
2.44M
Relative Volume:
0.69
Capitalizzazione di mercato:
$680.08B
Reddito:
$45.04B
Utile/perdita netta:
$10.59B
Rapporto P/E:
64.66
EPS:
11.71
Flusso di cassa netto:
$414.30M
1 W Prestazione:
+4.26%
1M Prestazione:
-6.92%
6M Prestazione:
-17.10%
1 anno Prestazione:
+0.85%
Intervallo 1D:
$751.49
$765.31
Intervallo di 1 settimana:
$689.00
$765.31
Portata 52W:
$677.09
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
757.18 | 680.08B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
153.62 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
ABBV
Abbvie Inc
|
176.80 | 312.76B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
64.49 | 286.27B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
109.93 | 217.12B | 51.72B | 11.94B | 13.81B | 5.88 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models - Benzinga
Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch - Benzinga
Is Eli Lilly and Company (LLY) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
Bernstein raises Eli Lilly stock price target to $1,100 By Investing.com - Investing.com India
Bernstein raises Eli Lilly stock price target to $1,100 - Investing.com
HHS Rejects Amgen, Lilly Fight of Clinics in Drug Discount Plan - Bloomberg Law News
Down 71%, Should You Buy the Dip on Viking Therapeutics Stock? - The Motley Fool
Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab And Tirzepatide Combination In Preclinical Model - MarketScreener
Eli Lilly and Company (LLY): One of the High Growth Forever Dividend Stocks to Invest In - Yahoo Finance
Eli Lilly (LLY) Sees Price Target Reduced by Guggenheim Ahead of Earnings | LLY Stock News - GuruFocus
Eli Lilly issues warning for Australia as Trump signals pharma tariffs - AFR
Eli Lilly's Mounjaro launch in India ignites wave of weight-loss enquiries - Reuters
Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data - Pharmaceutical Technology
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today - The Motley Fool
Jim Cramer on Eli Lilly and Company (LLY): “The Fastest Factory I’ve Ever Seen” - Insider Monkey
Eli Lilly Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) - Benzinga
Eli Lilly (LLY) Challenges OrderlyMeds Over Compounded Tirzepati - GuruFocus
Eli Lilly price target lowered to $928 from $973 at Guggenheim - TipRanks
Verve's 2nd swing at PCSK9 editing yields clean safety profile, teeing up Lilly opt-in decision - Fierce Biotech
Eli Lilly (LLY) Shows Strong Revenue Growth and Strategic Expans - GuruFocus
Eli Lilly (LLY) Boosts U.S. Manufacturing with $50 Billion Inves - GuruFocus
Eli Lilly Stock: Some Big News Is Incoming (NYSE:LLY) - Seeking Alpha
Eli Lilly's Obesity Drug Maintains Weight Loss for Three Years - MarketScreener
Notable analyst calls this week: Apple, Eli Lilly and Verizon stocks among top picks - Seeking Alpha
Novo, Lilly Patent Moves Keep GLP-1 Prices High, Report Says (3) - Bloomberg Law News
Lilly’s Zepbound Keeps Weight Off for Three Years, Study Finds - Bloomberg
Why Eli Lilly and Company (LLY) Is the Best Medical Stock to Buy According to Billionaires - Insider Monkey
Eli Lilly Drops $1.57B Bombshell--And Wall Street Shrugs It Off - Yahoo Finance
Eli Lilly Reverses Its Recent Run On Market Malaise. Is It A Sell? - Investor's Business Daily
Compounding pharmacy says Eli Lilly’s cease and desist letter means “nothing” - Sherwood News
OrderlyMeds Defies Eli Lilly (LLY) Cease-and-Desist Over Compoun - GuruFocus
Eli Lilly (LLY) Anticipates Q1 2025 Earnings Impact from Researc - GuruFocus
Personalized Medicine Market Forecast Report and Company Analysis 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La RocheResearchAndMarkets.com | FinancialContent - FinancialContent
Novo Nordisk and Eli Lilly Bring Weight Loss Contest to India - outlookbusiness.com
The Zacks Analyst Blog Highlights Eli Lilly, American Express, Thermo Fisher, Steel Partners and Oil-Dri - Yahoo Finance
ITC Blocks Imports Of Copycats Of Eli Lilly Weight Loss Drug - Law360
Top Research Reports for Eli Lilly, American Express & Thermo Fisher - Yahoo Finance
Eli Lilly Estimates Q1 2025 Acquired IPR&D Charges Approximately $1.72 To EPS - MarketScreener
Novo, Lilly Patent Moves Keep GLP-1 Prices High, Report Says (1) - Bloomberg Law News
Behind the Scenes of Eli Lilly's Latest Options Trends - Benzinga
GLP-1 Agonists Market Key Players Analysis- Eli Lilly and Company, Sanofi, AstraZeneca, Novo Nordisk. - openPR.com
Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks - Yahoo Finance
Lilly backs $41M investment in Longwood Fund spinout - The Business Journals
FDA: Pharmacies' Bid To Keep Making Eli Lilly Drug Is 'Absurd' - Law360
Eli Lilly and Company (LLY): One of the High Growth Dividend Paying Stocks to Invest in - Insider Monkey
Trump-Powered Medicare Setback Adds Bullish Impetus for Eli Lilly & Co (LLY) Stock - markets.businessinsider.com
Lobbying Update: $60,000 of ELI LILLY AND COMPANY lobbying was just disclosed - Nasdaq
Eli Lilly & Co (LLY) Gets a Buy from Bank of America Securities - The Globe and Mail
Top Stock Movers Now: Delta, Apple, Eli Lilly, and More - Investopedia
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today - The Motley Fool
Eli Lilly & Company (LLY): Among Defensive Stocks Billionaire Ken Fisher Is Betting On - Insider Monkey
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
0.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):